Rafael Fonseca

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Myeloma: classification and risk assessment
    Rafael Fonseca
    Division of Hematology and Oncology, Mayo Clinic in Arizona, Scottsdale, AZ Electronic address
    Semin Oncol 40:554-66. 2013
  2. pmc Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma
    Scott Van Wier
    Haematologica 98:1586-92. 2013
  3. pmc Molecular pathogenesis of Waldenstrom's macroglobulinemia
    Esteban Braggio
    Department of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Boulevard, Collaborative Research Building, Room 1 105, Scottsdale, AZ 85259 5494, USA
    Haematologica 97:1281-90. 2012
  4. doi request reprint Frontline treatment of multiple myeloma
    Rafael Fonseca
    Mayo Clinic Cancer Center, Center for Individualized Medicine, 13400 East Shea Boulevard, Collaborative Research Building, 1 105 Scottsdale, AZ 85259 5494, USA
    Hematology 17:S101-4. 2012
  5. ncbi request reprint Waldenström macroglobulinaemia
    Rafael Fonseca
    Division of Hematology Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA
    Br J Haematol 138:700-20. 2007
  6. ncbi request reprint Clinical and biologic implications of recurrent genomic aberrations in myeloma
    Rafael Fonseca
    Mayo Cinic Division of Hematology, Department of Laboratory Medicine, Rochester, MN 55905, USA
    Blood 101:4569-75. 2003
  7. ncbi request reprint Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
    Rafael Fonseca
    Mayo Clinic Department of Hematology and Internal Medicine, Minneapolis, MN 55905, USA
    Blood 99:3735-41. 2002
  8. ncbi request reprint Prognostic factors and staging in multiple myeloma
    Rafael Fonseca
    Mayo Clinic Arizona, 13208 East Shea Boulevard, Collaborative Research Building, 3 006, Scottsdale, AZ 85259 5494, USA
    Hematol Oncol Clin North Am 21:1115-40, ix. 2007
  9. ncbi request reprint Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach
    Rafael Fonseca
    Mayo Clinic, 13208 East Shea Boulevard, Collaborative Research Building 3 006, Scottsdale, AZ 85259 5494, USA
    Mol Cancer Ther 6:802-10. 2007
  10. pmc International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
    R Fonseca
    Department of Hematology Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AR 85259 5494, USA
    Leukemia 23:2210-21. 2009

Research Grants

Detail Information

Publications131 found, 100 shown here

  1. doi request reprint Myeloma: classification and risk assessment
    Rafael Fonseca
    Division of Hematology and Oncology, Mayo Clinic in Arizona, Scottsdale, AZ Electronic address
    Semin Oncol 40:554-66. 2013
    ..The continued search for genetic abnormalities that underlie the biology of MM may allow for even better precision therapy in the future. ..
  2. pmc Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma
    Scott Van Wier
    Haematologica 98:1586-92. 2013
    ..It is provocative to hypothesize that hypodiploid multiple myeloma is an advanced stage of non-hyperdiploid multiple myeloma. ..
  3. pmc Molecular pathogenesis of Waldenstrom's macroglobulinemia
    Esteban Braggio
    Department of Hematology Oncology, Mayo Clinic in Arizona, 13400 East Shea Boulevard, Collaborative Research Building, Room 1 105, Scottsdale, AZ 85259 5494, USA
    Haematologica 97:1281-90. 2012
    ..In addition, the low number of in vitro or in vivo models significantly challenges extensive analysis. In this manuscript, we review the molecular basis of this disease...
  4. doi request reprint Frontline treatment of multiple myeloma
    Rafael Fonseca
    Mayo Clinic Cancer Center, Center for Individualized Medicine, 13400 East Shea Boulevard, Collaborative Research Building, 1 105 Scottsdale, AZ 85259 5494, USA
    Hematology 17:S101-4. 2012
    ..Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment...
  5. ncbi request reprint Waldenström macroglobulinaemia
    Rafael Fonseca
    Division of Hematology Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA
    Br J Haematol 138:700-20. 2007
    ..Novel treatments, such as bortezomib, oblimersen sodium, perifosine and others are being evaluated...
  6. ncbi request reprint Clinical and biologic implications of recurrent genomic aberrations in myeloma
    Rafael Fonseca
    Mayo Cinic Division of Hematology, Department of Laboratory Medicine, Rochester, MN 55905, USA
    Blood 101:4569-75. 2003
    ..More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations...
  7. ncbi request reprint Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
    Rafael Fonseca
    Mayo Clinic Department of Hematology and Internal Medicine, Minneapolis, MN 55905, USA
    Blood 99:3735-41. 2002
    ..These patients do not have a worsened prognosis as previously thought...
  8. ncbi request reprint Prognostic factors and staging in multiple myeloma
    Rafael Fonseca
    Mayo Clinic Arizona, 13208 East Shea Boulevard, Collaborative Research Building, 3 006, Scottsdale, AZ 85259 5494, USA
    Hematol Oncol Clin North Am 21:1115-40, ix. 2007
    ..In addition, information on proliferative activity of plasma cells may be of value. The introduction of novel methods of prognostication should be strongly considered in all clinical trials...
  9. ncbi request reprint Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach
    Rafael Fonseca
    Mayo Clinic, 13208 East Shea Boulevard, Collaborative Research Building 3 006, Scottsdale, AZ 85259 5494, USA
    Mol Cancer Ther 6:802-10. 2007
    ....
  10. pmc International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
    R Fonseca
    Department of Hematology Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AR 85259 5494, USA
    Leukemia 23:2210-21. 2009
    ..This group proposes that genetic testing needs to be incorporated into daily clinical practice and also as an essential component of all ongoing and future clinical trials...
  11. ncbi request reprint The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
    Rafael Fonseca
    Mayo Clinic Division of Hematology, The Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Blood 102:2562-7. 2003
    ..The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter...
  12. doi request reprint Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial
    Rafael Fonseca
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Clin Lymphoma Myeloma 8:315-7. 2008
    ..By using an alkylator-free consolidation and reserving stem cell transplantation until the time of relapse, we hope that these treatment strategies will further prolong the survival of patients with myeloma...
  13. ncbi request reprint Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
    R Fonseca
    Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ 85259, USA
    Leukemia 20:2034-40. 2006
    ..Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis...
  14. ncbi request reprint Cytogenetic abnormalities in multiple myeloma
    R Fonseca
    Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Hematol Oncol Clin North Am 13:1169-80, viii. 1999
    ..It is likely that in the future, knowledge of the cytogenetic composition will be an integral part of the evaluation of myeloma patients...
  15. ncbi request reprint Genetics and cytogenetics of multiple myeloma: a workshop report
    Rafael Fonseca
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 64:1546-58. 2004
    ..Areas in need of further study were identified. The study of the genetic aberrations will likely form the platform for targeted therapy for the disease...
  16. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  17. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  18. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  19. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  20. pmc Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    Joseph R Mikhael
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Blood 119:4391-4. 2012
    ..It is well tolerated with few side effects. CyBorD warrants continued investigation as treatment for AL...
  21. doi request reprint A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Meaghan L Khan
    Hematology Oncology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Br J Haematol 156:326-33. 2012
    ..In conclusion, CyBorD demonstrated superior responses and less frequent serious toxicity but more neuropathy when compared to RD and CRD. Importantly, 80% of patients treated with modern therapeutic approaches are alive at 4years...
  22. ncbi request reprint Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 356:2582-90. 2007
    ..Prognostic factors for the progression and outcome of this disease are unclear...
  23. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  24. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  25. doi request reprint Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  26. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  27. pmc Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
    Martha Q Lacy
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 118:2970-5. 2011
    ..Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896...
  28. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  29. ncbi request reprint Genomic abnormalities in monoclonal gammopathy of undetermined significance
    Rafael Fonseca
    Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:1417-24. 2002
    ..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM...
  30. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  31. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  32. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  33. ncbi request reprint Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, Arizona, USA
    Cancer Res 67:2982-9. 2007
    ..Furthermore, the signatures that defined these clusters may provide a basis for tailoring treatment to individual patients...
  34. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  35. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  36. doi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  37. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
    ..Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL...
  38. pmc Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia
    Esteban Braggio
    Mayo Clinic, Scottsdale, Arizona 85259 5494, USA
    Cancer Res 69:3579-88. 2009
    ....
  39. ncbi request reprint A phase II trial of imatinib in patients with refractory/relapsed myeloma
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 47:39-42. 2006
    ..Patients ended treatment due to progressive disease (18 patients), death (3) and other (2). The data suggest that imatinib is not an active agent in patients with relapsed or refractory multiple myeloma...
  40. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  41. pmc Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma
    Jonathan J Keats
    Comprehensive Cancer Center, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Cancer Cell 12:131-44. 2007
    ..These results highlight the critical importance of the NF-kappaB pathway in the pathogenesis of multiple myeloma...
  42. pmc Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, NY, USA
    Blood 119:5397-404. 2012
    ..We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896...
  43. pmc Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 119:2100-5. 2012
    ..Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers...
  44. pmc Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
    Shaji K Kumar
    Division of Hematology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Blood 118:4359-62. 2011
    ..74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475...
  45. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  46. doi request reprint A novel report of cig-FISH and cytogenetics in POEMS syndrome
    Alan H Bryce
    Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 83:840-1. 2008
    ..Three patients had IgH translocation t(11;14)(q13;q32). No abnormalities were seen at 17p13(p53). The monosomy 13 is in line with other plasma cell disorders while the low prevalence of hyperdiploidy and abnormalities at 14q32 is unique...
  47. pmc Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2
    Bonnie K Arendt
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 112:1931-41. 2008
    ..Moreover, these cell lines will provide an invaluable tool to better understand AL, from the combined perspectives of amyloidogenic protein structure and amyloid formation, genetics, and cell biology...
  48. ncbi request reprint Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma
    Michael A Thompson
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Br J Haematol 123:305-8. 2003
    ..01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy...
  49. ncbi request reprint 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
    Roelandt F J Schop
    Mayo Clinic Comprehensive Cancer Center and Division of Hematology and Oncology, Mayo Clinic Scottsdale, 3 001, Scottsdale, AZ 89259, USA
    Cancer Genet Cytogenet 169:150-3. 2006
    ..The area of minimal deletion was between 6q23 and 6q24.3, but the deletion usually encompassed a large fragment of the 6q arm. These results indicate that 6q- can distinguish WM from IgM MGUS and is likely to be a secondary event...
  50. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  51. ncbi request reprint The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 111:1603-9. 2008
    ..Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis...
  52. pmc Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach
    Angela Baker
    Translational Genomics Research Institute, Phoenix, AZ, USA
    Blood 121:3147-52. 2013
    ..gov, number NCT00098475. ECOG E9487 is a companion validation set to the ECOG study E9486 and is registered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number EST-9486...
  53. pmc A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
    Wee Joo Chng
    Mayo Clinic Scottsdale, Comprehensive Cancer Center and Division of Hematology and Onocology, Scottsdale, AZ 85259, USA
    Blood 106:2156-61. 2005
    ..This percentage (40%) is remarkably similar to the percentage of hyperdiploid MM reported in the literature, suggesting that hyperdiploid MM may originate early during disease evolution...
  54. pmc AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
    Marta Chesi
    Comprehensive Cancer Center, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Cancer Cell 13:167-80. 2008
    ....
  55. pmc Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
    Wee J Chng
    Department of Hematology Oncology, Mayo Clinic Scottsdale, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259, USA
    Blood 108:2755-63. 2006
    ..Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue...
  56. pmc Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
    Yuan Xiao Zhu
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ, USA
    Blood 118:4771-9. 2011
    ..In summary, CRBN is an essential requirement for IMiD activity and a possible biomarker for the clinical assessment of antimyeloma efficacy...
  57. pmc Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4860-7. 2012
    ..The trial was registered at www.clinicaltrials.gov (NCT00564889)...
  58. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  59. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  60. ncbi request reprint Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:827-30. 2003
    ..008). The prognostic value of circulating PBPCs may help select treatment for patients with AL...
  61. ncbi request reprint Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
    Roshini S Abraham
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 105:794-803. 2005
    ..This study provides new insight into the molecular profile of clonal plasma cells and its functional relevance in the pathogenesis of light chain amyloidosis...
  62. ncbi request reprint Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions
    Roelandt F J Schop
    Department of Hematology and Internal Medicine and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:2996-3001. 2002
    ..However, WM tumor cells, which appear to be diploid or near diploid, often have deletions of 6q21...
  63. pmc Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:2837-40. 2005
    ..The presence of t(4;14) identifies a subset of patients whose time to progression is only 8.2 months. These patients receive minimal benefit from autologous stem cell transplantation and are candidates for novel therapeutic approaches...
  64. ncbi request reprint Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study
    Rafael Fonseca
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:715-20. 2002
    ..03). The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features...
  65. ncbi request reprint Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia
    Irene M Ghobrial
    Division of Hematology, Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:158-64. 2006
    ..Beta2-microglobulin > or =4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM...
  66. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
    ..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma...
  67. pmc Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity
    Rodger E Tiedemann
    Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
    J Clin Invest 118:1750-64. 2008
    ..These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies...
  68. ncbi request reprint Clinical course of patients with relapsed multiple myeloma
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:867-74. 2004
    ..To study the clinical course of patients with multiple myeloma (MM) that relapses after initial therapy...
  69. ncbi request reprint Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4319-23. 2002
    ..Thalidomide, an agent with antiangiogenic properties, is effective in relapsed myeloma. We report the results of a study combining thalidomide and dexamethasone as initial therapy for myeloma...
  70. ncbi request reprint Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
    ..To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma...
  71. pmc Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis
    Alan H Bryce
    Divison of Hematology, Mayo Clinic, 200 First Street, S W, Rochester, MN 55905, USA
    Haematologica 94:380-6. 2009
    ..Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis...
  72. pmc Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
    David J Inwards
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 113:108-16. 2008
    ..The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL)...
  73. ncbi request reprint Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Amyloid 10:257-61. 2003
    ..Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide...
  74. pmc Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy
    Neil E Kay
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 203:161-8. 2010
    ..1 deletion and in the more favorable genetic subtype characterized by the presence of 13q14.1 deletion. This aCGH study adds information on the association between poor trial response and increasing genetic complexity as CLL progresses...
  75. doi request reprint Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility
    Gregory J Ahmann
    Comprehensive Cancer Center and Division of Hematology and Oncology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    Cancer Epidemiol Biomarkers Prev 17:666-73. 2008
    ..Despite minor differences, our results suggest that shipment of samples did not significantly affect these quality determinants in aggregate...
  76. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  77. pmc Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    S Vincent Rajkumar
    Mayo Clinic, Rochester, Minnesota, USA
    Lancet Oncol 11:29-37. 2010
    ..High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide...
  78. ncbi request reprint Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study
    Irene M Ghobrial
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 101:2593-8. 2004
    ..The goal of the current study was to characterize the initial upsurge in immunoglobulin M (IgM) levels after treatment with rituximab in patients with Waldenstrom macroglobulinemia (WM)...
  79. pmc Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma
    W J Chng
    Department of Hematology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
    Leukemia 24:833-42. 2010
    ..On further analysis, the prognostic impact of 1p31-32 loss is due to shortening of post-relapse survival as there is no impact on complete response rates and progression-free survival...
  80. ncbi request reprint Genetics and cytogenetics of Waldenstrom's macroglobulinemia
    Roelandt F J Schop
    Mayo Clinic, Department of Hematology and Internal Medicine, Rochester, MN, USA
    Semin Oncol 30:142-5. 2003
    ..Having found deletions of the long arm of chromosome 6 as the only recurrent aberration, we speculate that a gene involved in B-cell maturation or survival at this locus may be inactivated as a cause of WM...
  81. ncbi request reprint Prognostic and therapeutic significance of myeloma genetics and gene expression profiling
    A Keith Stewart
    Hematology Oncology, Room 3 008, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    J Clin Oncol 23:6339-44. 2005
    ..Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification...
  82. ncbi request reprint Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression
    Roelandt F J Schop
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 132:55-60. 2002
    ..Deletions of these two regions are uncommon in WM, being more common in the late stages of the disease, thus unlikely playing a role in primary disease pathogenesis...
  83. ncbi request reprint Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 18:624-7. 2004
    ..Although not conclusive, this result lends further support to the hypothesis that angiogenesis is a relevant therapeutic target in myeloma...
  84. ncbi request reprint Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis
    S R Hayman
    Departments of Hematology and Internal Medicine and of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 98:2266-8. 2001
    ..2%) of those had translocation (11;14)(q13;q32) for an overall prevalence of the abnormality of 55%. IgH translocations are common in AL, especially the t(11;14)(q13;q32)...
  85. doi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  86. doi request reprint International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    A Dispenzieri
    Department of Hematology Laboratory Medicine Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:215-24. 2009
    ..This paper provides consensus guidelines for the use of this important assay, in the diagnosis and management of clonal PCD...
  87. doi request reprint Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
    Martha Q Lacy
    Mayo Clinic, Divisions of Hematology and Cardiovascular Diseases, Rochester, MN, USA
    J Clin Oncol 26:3196-203. 2008
    ..A phase I first-in-human study was conducted to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the anti-insulinlike growth factor 1 receptor (IGF-IR) monoclonal antibody CP-751,871...
  88. ncbi request reprint Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:431-6. 2006
    ..To determine if thalidomide plus dexamethasone yields superior response rates compared with dexamethasone alone as induction therapy for newly diagnosed multiple myeloma...
  89. ncbi request reprint POEMS syndrome: definitions and long-term outcome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2496-506. 2003
    ..Additional features of the syndrome often develop, but the complications of classic multiple myeloma rarely develop...
  90. pmc Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
    Gordon W Dewald
    Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Blood 106:3553-8. 2005
    ....
  91. ncbi request reprint Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Stabile 628, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5347-56. 2005
    ..This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL...
  92. ncbi request reprint Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points
    Angela Dispenzieri
    Mayo Clinic Rochester, MN 55905, USA
    Haematologica 91:390-3. 2006
    ..No anti-myeloma activity was observed in vivo. As administered, flavopiridol has disappointing activity as a single agent in advanced myeloma...
  93. pmc Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 111:785-9. 2008
    ..The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM...
  94. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  95. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  96. ncbi request reprint Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL)
    Roshini S Abraham
    Division of Hematology, Stabile 6 28, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Immunol 24:340-53. 2004
    ..Additionally, mutational clusterspots were identified at specific positions in the nucleotide and deduced protein sequence that could potentially contribute to destabilizing interactions resulting in a propensity to form amyloid...
  97. ncbi request reprint Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)
    Roshini S Abraham
    Division of Clinical Biochemistry and Immunology, Mayo Cancer Center, Mayo Clinic, Rochester, MN, USA
    Blood 101:3801-8. 2003
    ..The presence of renal disease, on the other hand, was associated with improved survival. Therefore, identification of the clonal VL gene in AL has important implications in determining clinical outcome...
  98. pmc Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
    Rodger E Tiedemann
    Division of Hematology Oncology, Mayo Clinic Arizona, 13400 Shea Blvd, Scottsdale, AZ 85259, USA
    Blood 115:1594-604. 2010
    ..As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma...
  99. ncbi request reprint Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors
    C L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 16:2377-81. 1998
    ..Anecdotal information suggested a low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem...
  100. pmc Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial
    A Dispenzieri
    Department of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1406-11. 2010
    ..In high-risk patients, upfront bortezomib results in response rates that are comparable to those reported for unselected cohorts, but single agent bortezomib is not sufficient as primary therapy...
  101. pmc Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1498-505. 2010
    ..A system including both these risk factors allows better prediction of outcome...

Research Grants12

  1. CHROMOSOMAL ABNORMALITIES IN MYELOMA AS DETECTED BY FISH
    Rafael Fonseca; Fiscal Year: 2007
    ..4. To establish the prognostic significance of delta13 in MM patients undergoing high-dose chemotherapy with stem cell support and contrast this to the effect of delta13 on survival in MM patients treated with conventional chemotherapy. ..
  2. CHROMOSOMAL ABNORMALITIES IN MYELOMA AS DETECTED BY FISH
    Rafael Fonseca; Fiscal Year: 2002
    ..Variables will also be studied using a multiple-variable model to test them as independent predictors. ..
  3. CHROMOSOMAL ABNORMALITIES IN MYELOMA AS DETECTED BY FISH
    Rafael Fonseca; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: This grant proposal aims to better define which treatments should be given to which genetic subtypes of myeloma, to provide optimal and risk adapted therapy for patients. ..